Positive Press Coverage Likely to Affect Alexion Pharmaceuticals (ALXN) Share Price

Marco Green
May 24, 2017

The stock presently has an average rating of "Buy" and an average price target of $168.10. Its down 3.33% from 5.93 million shares previously. Tudor Et Al has 0.01% invested in Alexion Pharmaceuticals, Inc.

On 2/28/2017 Carsten Thiel, EVP, sold 125 with an average share price of $74.52 per share and the total transaction amounting to $9,315.00. About 11.15 million shares traded or 460.30% up from the average.

The company maintained ROI for the last twelve months at 4.20%. Following the completion of the transaction, the senior vice president now owns 29,646 shares in the company, valued at $3,902,895.90. Camarda Finance Advsrs Ltd Limited Liability Company holds 0% of its portfolio in Alexion Pharmaceuticals, Inc. The stock rose 0.53% or $0.6 reaching $114.44 per share. About 110,667 shares traded. It has outperformed by 15.18% the S&P500. Alexion Pharmaceuticals's quarterly revenue was up 24.3% on a year-over-year basis. While the stock price moved along with the volume change, shares are touching $105.19. The original version of this news story can be accessed at https://www.chaffeybreeze.com/2017/05/19/positive-press-coverage-likely-to-affect-alexion-pharmaceuticals-alxn-share-price.html. Livforsakringsbolaget Skandia Omsesidigt reported 0.09% of its portfolio in Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has declined 18.12% since May 22, 2016 and is downtrending. The 1-year high was reported on May, 23 by Barchart.com. Including today's unusual volume, Alexion Pharmaceuticals, Inc.'s stock is performing at -5.66% on the year.

Investors sentiment is 1.07 in 2016 Q4. Its the same as in 2016Q3. Any way you dice it, a dip below $111.55 a share would be very bad news for ALXN's technical picture in the near-term. Susquehanna Gp Limited Liability Partnership accumulated 362,548 shares. Tocqueville Asset Mngmt L P owns 0.1% invested in Alexion Pharmaceuticals, Inc.

5/9/2017-Raymond James Financial, Inc. Finally, Greenwood Capital Associates LLC purchased a new stake in shares of Alexion Pharmaceuticals during the fourth quarter worth about $202,000. (NASDAQ:ALXN) shares. BELL LEONARD sold $1.10 million worth of stock. Institutions are now holders of 96.80% of the shares. Vanguard Group Inc. increased its stake in Alexion Pharmaceuticals by 3.1% in the first quarter.

Among 22 analysts covering Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) was sold by Moriarty John B on Monday, February 6. Therefore 73% are positive.

ALXN has been the subject of a number of analyst reports. Cantor Fitzgerald maintained JD Sports Fashion PLC (LON:JD) on Thursday, January 12 with "Buy" rating. They issued a "hold" rating for the company. The company was maintained on Monday, November 28 by Investec. Barclays Capital maintained the stock with "Equal-Weight" rating in Thursday, February 4 report. A downgrade to "neutral" from "overweight" at J.P. Morgan Securities is adding more pressure, with the brokerage saying the executive shake-up "will not help waning confidence in ALXN shares". Credit Suisse has "Outperform" rating and $165 target. About 13.37M shares traded or 571.86% up from the average. RBC Capital Markets initiated the stock with "Outperform" rating in Wednesday, July 13 report. Jefferies maintained it with "Hold" rating and $120 target in Friday, September 23 report. Acrospire Investment Management LLC now owns 1,200 shares of the biopharmaceutical company's stock worth $147,000 after buying an additional 400 shares in the last quarter. (NASDAQ:ALXN) for 925,384 shares.

Since December 19, 2016, it had 9 insider buys, and 0 sales for $995,452 activity. O'Neill Julie had sold 1,574 shares worth $206,841 on Monday, February 27. $6,791 worth of Alexion Pharmaceuticals, Inc. On Monday, February 6 Carmichael Clare sold $449,135 worth of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) shares were sold by Wagner Heidi L.

12/12/2016 - Alexion Pharmaceuticals, Inc. had its "neutral" rating reiterated by analysts at Wedbush. (NASDAQ:ALXN) for 51,906 shares. Nippon Life Ins invested in 0.03% or 11,613 shares. Its down 0.64, from 1.3 in 2016Q3. Adirondack Trust Com invested in 85 shares. 22 funds opened positions while 30 raised stakes. Federated Invsts Pa owns 18,657 shares. Nomura Holdg Incorporated invested in 0.01% or 32,350 shares. Finemark Bancshares Trust reported 114 shares stake. Commonwealth Bankshares Of invested in 946 shares. Old National Comml Bank In has 14,723 shares. Jpmorgan Chase & holds 0% or 10,579 shares. State Bank Of Nova Scotia reported 0% stake.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER